Drug intelligence / Profile preview

Longqing Capsules

Development stage: Unknown
Lead developer: Chongqing Kerui Nanhai Pharmaceutical
Administration: Oral

Overview

Longqing Capsules (癃清胶囊) is a Traditional Chinese Medicine (TCM) product developed and manufactured by Chongqing Kerui Pharmaceutical. It is an approved pharmaceutical in China, primarily indicated for the treatment of urinary tract infections (UTI), chronic prostatitis, and symptoms associated with 'heat-strangury' (re-lin) in TCM theory, including frequent, urgent, and painful urination. The formulation is composed of several herbal extracts, including *Scutellaria baicalensis*, *Rheum palmatum*, and *Taraxacum mongolicum*, which are traditionally recognized for their heat-clearing, detoxifying, and diuretic properties. It functions by reducing inflammation and inhibiting bacterial growth in the urogenital tract.

Brand names: Longqing Capsules癃清胶囊
Other names: Longqing Jiaonang

Beyond the preview

Go deeper on Longqing Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longqing Capsules.

Explore the full profile